COVID-19 Disease

Infectious Diseases
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Bavarian Nordic
Bavarian NordicDenmark - Kvistgard
2 programs
1
1
ABNCoV2Phase 31 trial
ABNCoV2 100ugPhase 21 trial
Active Trials
NCT05077267Completed197Est. Oct 2023
NCT05329220Completed4,205Est. Oct 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Bavarian NordicABNCoV2
Bavarian NordicABNCoV2 100ug

Clinical Trials (2)

Total enrollment: 4,402 patients across 2 trials

ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2

Start: Aug 2022Est. completion: Oct 20234,205 patients
Phase 3Completed

ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects

Start: Aug 2021Est. completion: Oct 2023197 patients
Phase 2Completed

Related Jobs in Infectious Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space